Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion in cash, securing global rights to the marketed pediatric low‑grade glioma drug Ojemda and Day One’s rare oncology portfolio. The deal price represents a substantial premium to Day One's share price and aims to broaden Servier’s rare cancer pipeline. Ojemda, approved in 2024 for pediatric low‑grade glioma, is the centerpiece of the transaction; Servier said the acquisition will also accelerate development of Day One’s experimental agents for rare tumors. The transaction adds a marketed oncology asset plus development programs that fit Servier’s specialty focus and delivers immediate commercial revenues alongside pipeline expansion. Strategically, the deal underscores large pharmas’ continued willingness to pay for marketed orphan oncology assets to secure short‑term revenues and near‑term regulatory assets for global rollout.